AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38358542 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus bevacizumab (200 mg and 15 mg/kg respectively) combined with radiotherapy (30-50 Gy/10 fractions)
Number of subjects: 46
Study 38358542 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus bevacizumab combined with radiotherapy
Number of subjects: 46
Study 38358703 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced adaptive disclosure (AD-E)
Number of subjects: 174
Study 38358703 — intervention group
Group type: COMPARATOR
Intervention: Present-centered therapy (PCT)
Number of subjects: 174
Study 38358711 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist Quality Scale (TQS)
Number of subjects: 66
Study 38358753 — intervention group
Group type: EXPERIMENTAL
Intervention: pegargiminase-chemotherapy (36.8 mg/m2 weekly intramuscularly)
Number of subjects: 249
Study 38358753 — intervention group
Group type: COMPARATOR
Intervention: placebo-chemotherapy
Number of subjects: 249
Study 38358753 — intervention group
Group type: EXPERIMENTAL
Intervention: pegargiminase-chemotherapy
Number of subjects: 249
Study 38358787 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone@BC app
Number of subjects: 45
Study 38359518 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 110
Study 38359518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 38359528 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy
Number of subjects: 214
Study 38359528 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-break
Number of subjects: 214
Study 38359542 — intervention group
Group type: EXPERIMENTAL
Intervention: START-Play intervention
Number of subjects: 112
Study 38359542 — intervention group
Group type: COMPARATOR
Intervention: Usual care early intervention (UC-EI)
Number of subjects: 112
Study 38359542 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with significant motor delays
Number of subjects: 112
Study 38359542 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with mild motor delays
Number of subjects: 112
Study 38359838 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with psilocybin-assisted psychotherapy (PAP)
Number of subjects: 30
Study 38359838 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 30
Study 38359854 — intervention group
Group type: COMPARATOR
Intervention: Rifasutenizol (50-1000 mg single doses)
Number of subjects: 246
Study 38359854 — intervention group
Group type: COMPARATOR
Intervention: Rifasutenizol (200-600 mg multiple doses, twice a day)
Number of subjects: 246
Study 38359854 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple regimen: 400 mg rifasutenizol, 20 mg rabeprazole, and 1 g amoxicillin twice a day for 14 days
Number of subjects: 246
Study 38359938 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 224
Study 38359938 — intervention group
Group type: COMPARATOR
Intervention: Radiography
Number of subjects: 224
Study 38359941 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (TOF)
Number of subjects: 2874
Study 38359944 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 1395
Study 38360182 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6-mg
Number of subjects: 652
Study 38360182 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 2-mg
Number of subjects: 652
Study 38360261 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial antiseizure medication (ASM)
Number of subjects: 39
Study 38360334 — intervention group
Group type: EXPERIMENTAL
Intervention: CureSight (binocular eye-tracking-based home treatment)
Number of subjects: 43
Study 38360452 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (20 Hz, 30 pulses/train, 25 trains, 10-s intertrain interval) applied for either 2 or 4 weeks (5 days/week)
Number of subjects: 135
Study 38360452 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS applied for 4 weeks
Number of subjects: 135
Study 38360485 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) - neural technique and area correction technique (group 1)
Number of subjects: 21
Study 38360485 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) - area correction technique (group 2)
Number of subjects: 21
Study 38360485 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study 38360494 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing of the whole body
Number of subjects: 314
Study 38360494 — intervention group
Group type: EXPERIMENTAL
Intervention: Showering
Number of subjects: 314
Study 38360494 — intervention group
Group type: EXPERIMENTAL
Intervention: Leave-on products application on the face
Number of subjects: 314
Study 38360494 — intervention group
Group type: EXPERIMENTAL
Intervention: Leave-on products application on the whole body
Number of subjects: 314
Study 38360494 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin care interventions delivery
Number of subjects: 314
Study 38360494 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterogeneity of product names
Number of subjects: 314
Study 38360494 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal hygiene and cleansing interventions
Number of subjects: 314
Study 38360494 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily washing
Number of subjects: 314
Study 38360494 — intervention group
Group type: EXPERIMENTAL
Intervention: Leave-on products usage
Number of subjects: 314
Study 38360494 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of skin integrity
Number of subjects: 314
Study 38360494 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed decision making
Number of subjects: 314
Study 38360505 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care model with electronic clinical decision support (CDS)
Number of subjects: 189
Study 38360505 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline HbA1c≥ 74.9 mmol/mol (9%)
Number of subjects: 189
Study 38360505 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt modification proportions
Number of subjects: 189
Study 38360588 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 9973
Study 38360588 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet agents
Number of subjects: 9973
Study 38360588 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor functional outcome at 3 months
Number of subjects: 9973
Study 38360588 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor functional outcome at 12 months
Number of subjects: 9973
Study 38360588 — intervention group
Group type: COMPARATOR
Intervention: Northeastern and central region patients
Number of subjects: 9973
Study 38360684 — intervention group
Group type: EXPERIMENTAL
Intervention: short fibre DPN with EA
Number of subjects: 48
Study 38360684 — intervention group
Group type: COMPARATOR
Intervention: short fibre DPN with sham EA
Number of subjects: 48
Study 38360684 — intervention group
Group type: EXPERIMENTAL
Intervention: axonal DPN with EA
Number of subjects: 48
Study 38360684 — intervention group
Group type: COMPARATOR
Intervention: axonal DPN with sham EA
Number of subjects: 48
Study 38360686 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component pain management pathway facilitated by a pain management coordinator including preoperative education, risk identification, personalized analgesic prescriptions, and continued support up to 8 weeks post-op.
Number of subjects: 0
Study 38360686 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study 38360716 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-led home phototherapy
Number of subjects: 23
Study 38360739 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinylestradiol/levonorgestrel 30/150 μg
Number of subjects: 180
Study 38360739 — intervention group
Group type: COMPARATOR
Intervention: vitamin E 400 IU
Number of subjects: 180
Study 38360750 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated health services delivered in a mobile unit with peer navigation for 26 weeks
Number of subjects: 400
Study 38360750 — intervention group
Group type: COMPARATOR
Intervention: Peer navigation only for 26 weeks to access the same set of services delivered in community settings
Number of subjects: 400
Study 38361371 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic intervention, details on dosage and duration not specified
Number of subjects: 0
Study 38361371 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 38361924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell disease participants (StSt)
Number of subjects: 40
Study 38361940 — intervention group
Group type: EXPERIMENTAL
Intervention: CROSS model
Number of subjects: 255
Study 38361978 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stimulation pulses
Number of subjects: 13
Study 38361978 — intervention group
Group type: COMPARATOR
Intervention: Static stimulation pulses
Number of subjects: 13
Study 38362052 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention through the tablet PC SUPERBRAIN application for 24 weeks, including managing metabolic and vascular risk factors, cognitive training, physical exercise, nutritional guidance, and boosting motivation.
Number of subjects: 300
Study 38362052 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group receiving no intervention during the study period.
Number of subjects: 300
Study 38362239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginge-Cal
Number of subjects: 30
Study 38362239 — intervention group
Group type: COMPARATOR
Intervention: Metapex
Number of subjects: 30
Study 38362338 — intervention group
Group type: EXPERIMENTAL
Intervention: M-atrial natriuretic peptide (single subcutaneous injection)
Number of subjects: 22
Study 38362338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 38362377 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision-based targeted therapies
Number of subjects: 716
Study 38362377 — intervention group
Group type: COMPARATOR
Intervention: Standard neoadjuvant chemotherapy
Number of subjects: 716
Study 38362377 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision-based targeted therapies in HR+/HER2+ subtype
Number of subjects: 716
Study 38362466 — intervention group
Group type: EXPERIMENTAL
Intervention: FLASH-RT (dose rate: 220-270 Gy/s)
Number of subjects: 60
Study 38362466 — intervention group
Group type: COMPARATOR
Intervention: CONV-RT (dose rate: 0.03-0.06 Gy/sec)
Number of subjects: 60
Study 38362466 — intervention group
Group type: EXPERIMENTAL
Intervention: FLASH-RT
Number of subjects: 60
Study 38362466 — intervention group
Group type: COMPARATOR
Intervention: CONV-RT
Number of subjects: 60
Study 38362600 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal therapy
Number of subjects: 0
Study 38362600 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38362629 — intervention group
Group type: EXPERIMENTAL
Intervention: hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG)
Number of subjects: 28
Study 38362818 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 173
Study 38362837 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR439459 administered intravenously at increasing doses every 2 weeks (Q2W) or every 3 weeks (Q3W) with cemiplimab IV at 3 mg/kg Q2W or 350 mg Q3W.
Number of subjects: 0
Study 38362837 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR439459 22.5 mg/kg with cemiplimab 350 mg IV Q3W.
Number of subjects: 0
Study 38362837 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR439459 ± cemiplimab
Number of subjects: 0
Study 38362837 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 0
Study 38362850 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC), followed by surgery and adjuvant chemotherapy (AC)
Number of subjects: 0
Study 38362850 — intervention group
Group type: COMPARATOR
Intervention: Surgery followed by adjuvant chemotherapy (AC)
Number of subjects: 0
Study 38362865 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECISE score
Number of subjects: 322
Study 38362871 — intervention group
Group type: EXPERIMENTAL
Intervention: Back School-based program
Number of subjects: 58
Study 38362871 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual lifestyle)
Number of subjects: 58
Study 38363272 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 5050
Study 38363272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5050
Study 38363314 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment seizures
Number of subjects: 48
Study 38363314 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical tumor resection
Number of subjects: 48
Study 38363314 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers having no formal education and lower household monthly income
Number of subjects: 48
Study 38363446 — intervention group
Group type: EXPERIMENTAL
Intervention: CR with BWSTT (n=16)
Number of subjects: 30
Study 38363446 — intervention group
Group type: COMPARATOR
Intervention: CR only (control group, n=14)
Number of subjects: 30
Study 38363461 — intervention group
Group type: EXPERIMENTAL
Intervention: Pruritus Numeric Rating Scale (Pruritus NRS)
Number of subjects: 21
Study 38363463 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat treatment (oral medicine for anemia in CKD)
Number of subjects: 444
Study 38363466 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat treatment (oral), specific dosage not mentioned, duration of treatment evaluated for 12 weeks.
Number of subjects: 2354
Study 38363467 — intervention group
Group type: EXPERIMENTAL
Intervention: Trofinetide
Number of subjects: 0
Study 38363467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38363571 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients receiving chemotherapy (n=110)
Number of subjects: 308
Study 38363571 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients with severe disease
Number of subjects: 308
Study 38363571 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients with SARS-CoV-2 reinfection (n=11)
Number of subjects: 308
Study 38363571 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients
Number of subjects: 308
Study 38363589 — intervention group
Group type: EXPERIMENTAL
Intervention: ICory-Circumcision (BuddyCare app and Triumf Health mobile game app)
Number of subjects: 6
Study 38363591 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual embodiment training sessions (8 sessions over 4 weeks)
Number of subjects: 24
Study 38363577 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilebesiran 150 mg, once every 6 months
Number of subjects: 394
Study 38363577 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilebesiran 300 mg, once every 3 months or every 6 months
Number of subjects: 394
Study 38363577 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilebesiran 600 mg, once every 6 months
Number of subjects: 394
Study 38363577 — intervention group
Group type: COMPARATOR
Intervention: Placebo, once every 3 months
Number of subjects: 394
Study 38363727 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment status
Number of subjects: 55
Study 38363727 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of cancer
Number of subjects: 55
Study 38363727 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnership status
Number of subjects: 55
Study 38363727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 55
Study 38363727 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis category
Number of subjects: 55
Study 38363733 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-question primary care level screening tool used by Community HIV-care Providers (CHiPs) to identify adolescents at risk of being HIV-positive.
Number of subjects: 42320
Study 38363733 — intervention group
Group type: COMPARATOR
Intervention: Universal testing and treatment (UTT) as part of the community-level combination HIV prevention package.
Number of subjects: 42320
Study 38363772 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional bread (200 g/d for 8 weeks)
Number of subjects: 31
Study 38363772 — intervention group
Group type: COMPARATOR
Intervention: Control bread (200 g/d for 8 weeks)
Number of subjects: 31
Study 38363872 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 352
Study 38363950 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip abductor and external rotator strengthening exercises with conventional physical therapy (CPT)
Number of subjects: 45
Study 38363950 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training with conventional physical therapy (CPT)
Number of subjects: 45
Study 38363950 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT) alone
Number of subjects: 45
Study 38363996 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Stress Test (EST)
Number of subjects: 164
Study 38363996 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiology Study (EPS)
Number of subjects: 164
Study 38363996 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk findings on EST
Number of subjects: 164
Study 38363996 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk EST findings with SPERRI/APERP ≤ 250 ms
Number of subjects: 164
Study 38364020 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (minimum 50 l/min)
Number of subjects: 60
Study 38364020 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive bilevel positive pressure ventilation (NIV)
Number of subjects: 60
Study 38364110 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxelotor
Number of subjects: 8
Study 38364185 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 0
Study 38364185 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture
Number of subjects: 0
Study 38364191 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 1050
Study 38364191 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1050
Study 38364196 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (Ro-CHOP)
Number of subjects: 0
Study 38364196 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)
Number of subjects: 0
Study 38364244 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of packed red blood cells (pRBCs)
Number of subjects: 3366
Study 38364831 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg once a day
Number of subjects: 313
Study 38364831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 38364832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib plus atezolizumab
Number of subjects: 432
Study 38364832 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 432
Study 38364832 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent cabozantinib
Number of subjects: 432
Study 38365073 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 38365073 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38365118 — intervention group
Group type: EXPERIMENTAL
Intervention: Evenly distributing protein across meals (25-30 g per meal)
Number of subjects: 43
Study 38365118 — intervention group
Group type: COMPARATOR
Intervention: Usual intake pattern (most protein at dinner)
Number of subjects: 43
Study 38365173 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + WET (Written Exposure Therapy)
Number of subjects: 102
Study 38365300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent system using deep learning and statistical learning algorithms for detecting congenital anomalies in fetal morphology ultrasound scans.
Number of subjects: 4000
Study 38365300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent system during testing phase on previously unseen scans.
Number of subjects: 4000
Study 38365379 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 78
Study 38365379 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 78
Study 38365417 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine administered to patients with G6PD normal status, aged ≥16 years, not pregnant or breastfeeding.
Number of subjects: 6075
Study 38365417 — intervention group
Group type: EXPERIMENTAL
Intervention: G6PD testing before tafenoquine administration.
Number of subjects: 6075
Study 38365417 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine administered to patients with intermediate or normal G6PD status, aged ≥6 months, not pregnant or breastfeeding >1 month.
Number of subjects: 6075
Study 38365437 — intervention group
Group type: COMPARATOR
Intervention: Single visit group (SV)
Number of subjects: 39809
Study 38365437 — intervention group
Group type: EXPERIMENTAL
Intervention: Return visit group (MV)
Number of subjects: 39809
Study 38365437 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 39809
Study 38365437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 39809
Study 38365437 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of comorbidities (e.g., cancer, obesity, organ transplant)
Number of subjects: 39809
Study 38365437 — intervention group
Group type: EXPERIMENTAL
Intervention: Current/prior substance use
Number of subjects: 39809
Study 38365437 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher temperature or WHO severe disease
Number of subjects: 39809
Study 38365437 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 39809
Study 38365437 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination status (boosted or fully vaccinated)
Number of subjects: 39809
Study 38365446 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended CPAP
Number of subjects: 36
Study 38365446 — intervention group
Group type: COMPARATOR
Intervention: Low-flow nasal cannula (NC)
Number of subjects: 36
Study 38365502 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 SC (body weight-based dosing every 2 weeks [Q2W]; W6-54)
Number of subjects: 112